Category: 287193-07-1

Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps. 287193-07-1, Name is Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate, molecular formula is C8H12O4. In a Article，once mentioned of 287193-07-1, Recommanded Product: Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate

Glucokinase (GK) activators represent a class of type 2 diabetes therapeutics actively pursued due to the central role that GK plays in regulating glucose homeostasis. Herein we report a novel C5-alkyl-2-methylurea-substituted pyridine series of GK activators derived from our previously reported thiazolylamino pyridine series. Our efforts in optimizing potency, enzyme kinetic properties, and metabolic stability led to the identification of compound 26 (AM-9514). This analogue showed a favorable combination of in vitro potency, enzyme kinetic properties, acceptable pharmacokinetic profiles in preclinical species, and robust efficacy in a rodent PD model.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Recommanded Product: Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate. In my other articles, you can also check out more blogs about 287193-07-1

Reference：
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

The dynamic chemical diversity of the numerous elements, ions and molecules that constitute the basis of life provides wide challenges and opportunities for research. 287193-07-1, Name is Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate, molecular formula is C8H12O4. In a Patent，once mentioned of 287193-07-1, Application In Synthesis of Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R1, R3 and R4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Application In Synthesis of Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate, you can also check out more blogs about287193-07-1

Reference：
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

Catalysts allow a reaction to proceed via a pathway that has a lower activation energy than the uncatalyzed reaction. In homogeneous catalysis, catalysts are in the same phase as the reactants.287193-07-1, C8H12O4. A document type is Patent, introducing its new discovery., Safety of Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate

Compounds of formula (I’): (I); wherein: R1 represents substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X represents-(CRkaRkb)k-; Rka and Rkb are each independently hydrogen or C1-6alkyl; k is 0-5; Y represents-NR3-or a bond; R3 represents hydrogen or C1-6alkyl; Z represents a moiety of formula (ZA), (ZB), (ZC), (ZD), (ZE), or (ZF); A represents-(CRjaRjb)j-; Rja and Rjb are each independently hydrogen or C1-6alkyl; j is 0, 1 or 2, and; R2 represents unsubstituted or substituted aryl; and salts and solvates thereof are CCR3 receptor antagonists and are thus indicated to be useful in therapy.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Safety of Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate. This is the end of this tutorial post, and I hope it has helped your research about 287193-07-1

Reference：
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

Synthetic Route of 287193-07-1, Children learn through play, and they learn more than adults might expect. Science experiments are a great way to spark their curiosity, get their minds active, and encourage them to do something that doesn’t involve a screen. An article , which mentions 287193-07-1, molecular formula is C8H12O4. The compound – Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate played an important role in people’s production and life.

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

If you are hungry for even more, make sure to check my other article about 287193-07-1. Synthetic Route of 287193-07-1

Reference：
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

Children learn through play, and they learn more than adults might expect. Science experiments are a great way to spark their curiosity, get their minds active, and encourage them to do something that doesn¡¯t involve a screen. 287193-07-1, C8H12O4. A document type is Patent, introducing its new discovery., name: Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate

Compounds of formula (I’): (I); wherein: R1 represents substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X represents-(CRkaRkb)k-; Rka and Rkb are each independently hydrogen or C1-6alkyl; k is 0-5; Y represents-NR3-or a bond; R3 represents hydrogen or C1-6alkyl; Z represents a moiety of formula (ZA), (ZB), (ZC), (ZD), (ZE), or (ZF); A represents-(CRjaRjb)j-; Rja and Rjb are each independently hydrogen or C1-6alkyl; j is 0, 1 or 2, and; R2 represents unsubstituted or substituted aryl; and salts and solvates thereof are CCR3 receptor antagonists and are thus indicated to be useful in therapy.

Interested yet? Keep reading other articles of 287193-07-1!, name: Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 287193-07-1, Name is Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate, molecular formula is C8H12O4. In a Patent£¬once mentioned of 287193-07-1, Application In Synthesis of Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate

IRAK INHIBITORS AND USES THEREOF

The present invention provides thieno[2,3-d]pyrimidine derivative compounds, and pharmaceutical compositions thereof. The invention also includes methods inhibiting an IRAK protein kinase in a patient by administering the thieno[2,3-d]pyrimidine derivative compound. The invention also includes methods of treating an IRAK-mediated disorder, disease, or condition in a patient by administering the thieno[2,3-d]pyrimidine derivative compound

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Application In Synthesis of Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate. In my other articles, you can also check out more blogs about 287193-07-1

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.287193-07-1,Ethyl 4-oxotetrahydro-2H-pyran-2-carboxylate,as a common compound, the synthetic route is as follows.

To a solution of 4-oxo-tetrahydro-2H-pyran-2-carboxylic acid ethyl (0.6 g, 3.5 mmol) in absolute ethanol (6 ml) was added sulfur (0.12 g, 3.85 mmol) and tert-butyl cyanoacetate (0.64 g, 4.55 mmol). The solution was stirred under nitrogen in a 50 C. oil bath and morpholin (0.61 ml, 7.0 mmol) was added. The reaction was stirred for 18 hours and then cooled to ambient temperature and excess sulfur removed by filtration. The filtrate was concentrated in vacuo and reconstituted in ethyl acetate (50 ml). The organic phase was washed with brine (2*10 ml), dried (Na2SO4), filtered, and the solvent evaporated in vacuo. The residue was purified by silica gel chromatography using a gradient of ethyl acetate/hexane (20 to 25% gradient) as eluent. Pure fraction of the two isomers were collected and the solvent evaporated in vacuo which afforded 0.47 g of 2-amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3,5-dicarboxylic acid 3-tert-butyl ester 5-ethyl ester (A) and 0.3 g of 2-amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3,7-dicarboxylic acid 3-tert-butyl ester 7-ethyl ester (B) in 62% combined yield. (A)1H-NMR (300 MHz, CDCl3) delta 5.96 (bs, 2H), 4.77-4.61 (m, 2H), 4.32-4.18 (m, 3H), 3.19-3.12 (m, 1H), 2.90-2.80 (m, 1H), 1.52 (s, 9H), 1.29 (t, 3H, J=7 Hz).(B)1H-NMR (300 MHz, CDCl3) delta 5.10 (s, 1H), 4.28-4.13 (m, 3H), 3.98-3.91 (m, 1H), 2.82-2.76 (m, 2H), 1.51 (s, 9H), 1.31 (t, 3H, J=7 Hz)., 287193-07-1

As the paragraph descriping shows that 287193-07-1 is playing an increasingly important role.

Reference£º
Patent; Novo Nordisk A/S; US7019026; (2006); B1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics